508. Avent CK, Krinsky D, Kirklin JK, et al. Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. *Am J Med* 1988 Sep; 85: 452-3
509. Elston RA, Taylor J. Possible interaction of ciprofloxacin with cyclosporin A [letter]. *J Antimicrob Chemother* 1988 May; 21: 679-80
510. Tan KK, Trull AK, Shawket S. Co-administration of ciprofloxacin and cyclosporin: lack of evidence for a pharmacokinetic interaction. *Br J Clin Pharmacol* 1989 Aug; 28: 185-7
511. Robinson JA, Venezio FR, Costanzo-Nordin MR, et al. Patients receiving quinolones and cyclosporine after heart transplantation. *J Heart Transplant* 1990 Jan-Feb; 9: 30-1
512. Ball AP. Ciprofloxacin: an overview of adverse experiences. *J Antimicrob Chemother* 1986; 18 Suppl. D: 187-93
513. Lomaestro BM, Lesar TS. Continuing problem of ciprofloxacin administered with interacting drugs. *Am J Hosp Pharm* 1994 Mar 15; 51: 832
514. Echols RM. The selection of appropriate dosages for intravenous ciprofloxacin. *J Antimicrob Chemother* 1993 May; 31: 783-7
515. Bauernfeind A. Questioning dosing regimens of ciprofloxacin. *J Antimicrob Chemother* 1993 May; 31: 789-98
516. Schaad UB. Use of the new quinolones in pediatrics. *Isr J Med Sci* 1994 May-Jun; 30: 463-8
517. Eliopoulos GM. In vitro activity of fluoroquinolones against Gram-positive bacteria. *Drugs* 1995; 49 Suppl. 2: 48-57

Correspondence: Rick Davis, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

Errata

Vol. 49, Suppl. 2, page 262: In the third column of table I, the heading should read *Minocycline*.

[Thomas D, Orfila J, Bissac E. Evaluation of the activity of different quinolones in the experimental chlamydial salpingitis mouse model. *Drugs* 1995; 49 Suppl. 2: 261-3

Vol. 51, No. 3, page 466: In section 1.2.1, the last sentence should read, '24-hour period (median 99%) . . . '.

page 467: In table I, the reference to Damann et al.^[18] should read *Dammann* et al.^[18].

page 468: In section 1.2.1, references 18, 19, 20 and 21 should be changed to references 19, 20, 21 and 22, respectively.

pages 468 to 469: In section 1.2.2, references 18 and 19 should be changed to references 19 and 20, respectively.

page 470: In section 1.6, reference 17 should be changed to reference 18.

page 474: In table III, columns 4 and 5 of the first two studies in the section regarding comparisons with ranitidine in patients with duodenal ulcer should read as follows:

Reference	No. of evaluable patients	Dosage (mg/day)	Cumulative ulcer healing rate (% patients)			Epigastric pain relief ^a (% patients)		Overall efficacy
			2wk	4wk	8wk	2wk	4wk	
Baccaro et al. ^[92]	170	P 40	83*	100				P ≥ R
		R 300	67	97				
Castro et al. ^[93]	222	P 40	75*	97*				P > R
		R 300	45	75				

[Fitton A, Wiseman L. Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders. *Drugs* 1996; 51: 460-82]